NeoStem
420 Lexington Avenue
Suite 350
New York, New York 10170
Telephone: 1.212.584.4180

Clinical Trial Information for Patients

Currently Active Clinical Trials

PreSERVE AMI

Enrollment in our PreSERVE AMI Phase 2 trial was completed in December 2013. Initial data from this trial will be released in the second half of 2014. The trial is a multicenter, randomized, double-blind, placebo-controlled U.S. clinical trial to evaluate the efficacy and safety of a single intra-coronary infusion of at least 10 million cells of AMR-001, post STEMI, in subjects with ejection fractions of 48% or less as measured by cardiac magnetic resonance imaging (“CMR”).

Read more about the clinical trial at clinicaltrials.gov.

Upcoming Clinical Trials

Please join our mailing list to learn more about NeoStem’s upcoming clinical trials as information becomes available. More information will be also be provided on this page.

Announced upcoming trials include:

  • Intus Study – Phase 3 trial for Stage IV or recurrent Stage III melanoma
  • Phase 2 trial of autologous regulatory T cell therapy for type 1 diabetes
  • Phase 1/2a trial of autologous regulatory T cell therapy for being developed for a steroid resistant asthma indication

 

NeoStem - Cell Therapy Development - Investors